- Bi J, Lau SH, Lv ZL, Xie D, Li W, Lai YR, Zhong JM, Wu HQ, Su Q, He YL, Zhan WH, Wen JM, Guan XY. Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Human Pathology 2009; 40: 1790-7.
- Daugaard S, Christensen LH, Høgdall E. Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40. APMIS 2009; 117: 518-28.
- Dei Tos AP, Pedeutour F. Atypical lipomatous tumour / well differentiated liposarcoma. In: World Health Organisation classification of tumours. Pathology and genetics of tumours of soft tissue and bone (Fletcher CDM, Unni KK, Mertens F, eds). IARCPress, Lyon 2002: 35–7.
- Dei Tos AP, Pedeutour F. Atypical lipomatous tumour. In: WHO classification of tumours of soft tissue and bone. International agency for research on cancer (Fletcher CDM, Brigde JA, Hogendoom PCW, Mertens F, eds). Lyon 2013: pp. 33–6.
- Faibish M, Francescone R, Bentley B, Yan W, Shao R. A YKL-40 neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol Cancer Ther. 2011; 10 (5): 742–51.
- Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, Vilain MO, Mandard AM, Le Doussal V, Leroux A, Jacquemier J, Duplay H, Sastre-Garau X, Costa J. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997; 15: 350–62.
- Gustafson P. Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. Acta Orthop Scand (suppl 259) 1994: 1-31.
- Høgdall EV, Ringsholt M, Høgdall CK, Christensen IJ, Johansen JS, Kjaer SK, Blaakaer J, Ostenfeld-Møller L, Price PA, Christensen LH. YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer 2009; 9: 8.
- Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodeling, fibrosis and cancer. Dan Med Bull 2006; 53: 172-209.
- Johansen JS, Høyer PE, Larsen LA, Price PA, Møllgård K. YKL-40 protein expression in the early developing human musculoskeletal system. J Histochem Cytochem 2007; 55: 1213-28.
- Johansen JS, Lottenburger T, Nielsen HJ, Jensen JE, Svendsen MN, Kollerup G, Christensen IJ. Diurnal, weekly and long-time variation in serum concentrations of YKL-40 in healthy subjects. Cancer Epidemiol Biomarkers Prev 2008; 17: 2603-8.
- Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40: a potential new cancer biomarker? Future Oncol 2009; 5: 1065-82.
- Lee CG, Hartl D, Lee GR, Koller B, Matsuura H, Da Silva CA, Sohn MH, Cohn L, Homer RJ, Kozhich AA, Humbles A, Kearley J, Coyle A, Chupp G, Reed J, Flavell RA, Elias JA. Role of breast regression protein 39 (BRP-39)/Chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med 2009; 206: 1149-66.
- Lee CG, Da Silva CA, Dela Cruz CS, Ahangari F, Ma B, Kang MJ, He CH, Takyar S, Elias JA. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol 2011; 73: 479-501
- Levine EA. Prognostic factors in soft tissue sarcoma. Semin Surg Oncol 1999; 17: 23–32.
- Pelloski CE, Mahajan A, Maor M, Chang EL, Woo S, Gilbert M, Colman H, Yang H, Ledoux A, Blair H, Passe S, Jenkins RB, Aldape KD. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res 2005; 1: 3326–34.
- Ramanathan RC, A’Hem R, Fisher C, Thomas JM. Prognostic Index for Extremity Soft Tissue Sarcomas With Isolated Local Recurrence. Ann Surg Oncol 2001; 8: 278–89.
- Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 1997; 43: 221-5
- Ringsholt M, Høgdall EV, Johansen JS, Price PA, Christensen LH. YKL-40 protein expression in normal adult human tissues – an immunohistochemical study. J Mol Histol 2007; 38: 33-43.
- Roslind A, Knoop AS, Jensen M, Johansen JS, Nielsen DL, Price PA, Balslev E. YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer. Breast Cancer Res Treat 2008; 112: 275–85.
- Rydholm A, Gustafson P. Should tumor depth be included in prognostication of soft tissue sarcoma? BMC Cancer 2003; 3: 17.
- Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with Mmetastatic melanoma. Cancer 2006; 106: 1130-9.
- Shao R, Hamel K, Petersen L, Cao QJ, Arenas RB, Bigelow C, Bentley B, Yan W. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 2009; 28: 4456-68.
- Singer S, Corson JM, Gonin R, Labow B, Eberlein TJ. Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma. Ann Surg 1994; 219: 165-73.
- Trojani M, Contesso G, Coindre JM, Rouesse J, Bui NB, de Mascarel A, Goussot JF, David M, Bonichon F, Lagarde C. Soft tissue sarcoma of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 1984; 33: 37-42.
- Yang GF, Cai PY, Li XM, Deng HX, He WP, Xie D. Expression and clinical significance of YKL-40 protein in epithelial ovarian cancer tissues. Chinese J Cancer 2009; 28: 142-5.
- Choose new content alerts to be informed about new research of interest to you
- Easy remote access to your institution's subscriptions on any device, from any location
- Save your searches and schedule alerts to send you new results
- Export your search results into a .csv file to support your research